Hypoglycaemia events with <scp>iGlarLixi</scp> versus premix biphasic insulin aspart 30 ( <scp>BIAsp</scp> 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the <scp>SoliMix</scp> trial

MLA

Rory J. McCrimmon, et al. “Hypoglycaemia Events with iGlarLixi versus Premix Biphasic Insulin Aspart 30 ( BIAsp 30) in People with Type 2 Diabetes Advancing from Basal Insulin: An Analysis of the SoliMix Trial.” Diabetes, Obesity and Metabolism, vol. 24, Aug. 2022, pp. 2391–99. EBSCOhost, https://doi.org/10.1111/dom.14825.

APA

Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, & Julio Rosenstock. (2022). Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial. Diabetes, Obesity and Metabolism, 24, 2391–2399. https://doi.org/10.1111/dom.14825

Chicago

Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, and Julio Rosenstock. 2022. “Hypoglycaemia Events with iGlarLixi versus Premix Biphasic Insulin Aspart 30 ( BIAsp 30) in People with Type 2 Diabetes Advancing from Basal Insulin: An Analysis of the SoliMix Trial.” Diabetes, Obesity and Metabolism 24 (August): 2391–99. doi:10.1111/dom.14825.